On November 3, 2022 Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in oncology, reported that four abstracts highlighting data on its pipeline assets have been selected for presentation at the upcoming 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, Ichnos Sciences, NOV 3, 2022, View Source [SID1234622951]). The meeting will be held December 10-13, 2022, in New Orleans, Louisiana.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These abstracts discuss three assets – ISB 1342, ISB 1442 and ISB 2001 – two of which are currently in Phase 1 clinical studies in relapsed/refractory multiple myeloma. The data to be presented will highlight the potential of the company’s proprietary BEAT platform1 and its growing momentum toward providing curative therapies that may extend and improve lives.
"Our work is grounded in the notion that cure is possible and the understanding that there is room for novel thinking in the pursuit of effective, disease-centric therapies for oncology," said Cyril Konto, M.D., President and Chief Executive Officer of Ichnos Sciences. "Ichnos is focused on harnessing the power of the immune system in the fight against cancer, and we are pleased to have been selected to present data supporting this approach at the ASH (Free ASH Whitepaper) Annual Meeting."
The full ASH (Free ASH Whitepaper) 2022 Annual Meeting abstracts are available for review at: View Source
Visit the Ichnos Sciences booth (#3127) to learn more about Ichnos’ proprietary BEAT platform, expanding pipeline of oncology assets, partnership opportunities and more.
Follow Ichnos on LinkedIn for more updates throughout the conference.